America's shale oil industry cannot be counted on for rapid supply increases. Investors, burned by past cycles of over-investment followed by price crashes, now demand capital discipline from producers. This prevents companies from chasing short-term price spikes with large spending increases, limiting their ability to quickly fill global supply gaps.

The biotech sector lacks mid-cap companies because successful small firms are typically acquired by large pharma before reaching that stage. This creates a barbell structure of many small R&D shops and a few commercial giants. The assets, not the companies, transition from small to large.

The U.S. oil boom is associated with shale (unconventional), but conventional reservoirs are geologically superior with higher porosity and permeability. They were the "easy" reservoirs to find and exploit historically. Today's industry focuses on harder-to-extract shale because most large conventional fields are already developed.

The current M&A landscape is defined by a valuation disparity where smaller companies trade at a discount to larger ones. This creates a clear strategic incentive for large corporations to drive growth by acquiring smaller, more affordable competitors.

Counterintuitively, making a business hyper-efficient before a sale is not always optimal. Roughly half of buyers prefer acquiring companies with identifiable inefficiencies because improving them is a key part of their own value-creation thesis and justification for the acquisition.

A spike in oil prices creates a cash windfall. Large, stable energy companies will direct this to buybacks and dividends. In contrast, smaller, more leveraged producers will seize the opportunity to pay down debt, improving their credit metrics and rewarding bondholders more directly.

Top compounders intentionally target and dominate small, slow-growing niche markets. These markets are unattractive to large private equity firms, allowing the compounder to build a durable competitive advantage and pricing power with little interference from deep-pocketed rivals.

Contrary to the "scale is everything" mantra, large private credit funds face diseconomies of scale. The pressure to deploy billions forces them to chase crowded, mainstream deals, leaving complex but lucrative niches like direct-origination ABL to smaller, more specialized firms that can manage the complexity.

The severe downturns of 2015-16 and 2020 forced US energy producers to deleverage, improve technology, and dramatically lower break-even costs. Now, many top-tier producers are profitable even with $40/barrel oil, making the sector far more resilient to price volatility than in previous cycles.